Latest News

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

Teva Announces Launch of Offering of Senior Notes

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.